This study is currently not recruiting participants.

An Open Label Phase Ib Dose-Escalation Study of TRC105 Combined with Standard-Dose Bevacizumab for Advanced Solid Tumors

Investigation of Safety and Tolerance of an Investigational Antibody with a Cancer Treatment

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this research study is to determine the safety of the TRC105 monoclonal antibody when given in combination with bevacizumab and how well you tolerate the combination.

Detailed description of study

The purpose of this research study is to determine the safety of the TRC105 monoclonal antibody when given in combination with bevacizumab and how well you tolerate the combination.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety of an investigational monoclonal antibody when used with another cancer treatment. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.

Participants in the study will receive the investigational antibody in combination with another treatment to see how well it is tolerated. Tolerance refers to how the body handles the treatment and any side effects that may occur.

  • Who can participate: Participants must meet specific eligibility criteria, including age and health status, to enroll in the study.
  • Study details: Participants will receive an investigational antibody along with another treatment to assess safety and tolerance.
Updated on 19 Feb 2024. Study ID: 1109006869

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team